MedTrace Logo

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

NCT03783403 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2024-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.

Conditions

  • Neoplasms

Interventions

DRUG

CC-95251

Specified dose on specified days

DRUG

Rituximab

Specified dose on specified days

DRUG

Cetuximab

Specified dose on specified days

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2024-08-05
Completion
2024-08-05
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • France
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03783403 on ClinicalTrials.gov